吉西他滨联合异环磷酰胺治疗难治性乳腺癌的临床效果分析

Analysis of clinical effect of Gemcitabine combined with Ifosfamide in treatment of refractory breast cancer

目的探究吉西他滨联合异环磷酰胺治疗难治性乳腺癌的临床效果。方法选择2014年2月~2015年2月在江苏省南京市第二医院接受治疗的98例乳腺癌患者作为本次试验的研究对象,按随机数字表法将其分为对照组与观察组,每组49例。对照组应用吉西他滨进行化疗,观察组应用吉西他滨联合异环磷酰胺治疗。治疗3个月后,比较两组的临床疗效,不良反应发生情况及生活质量水平。结果观察组治疗的总有效率为89.8%,高于对照组的65.3%,差异有统计学意义（P〈0.05）。观察组与对照组均出现不同程度的不良反应,两组不良反应发生率比较差异无统计学意义（P〉0.05）。治疗后,观察组患者生活质量改善率为89.90%,明显高于对照组的63.63%,差异有统计学意义（P〈0.05）。结论吉西他滨联合异环磷酰胺治疗难治性乳腺癌效果明显,且不良反应发生率较低,可明显提高患者的生活质量,有利于患者的恢复,为临床难治性乳腺癌联合用药方案的制订提供参考依据。

Objective To explore the clinical effect of Gemcitabine combined with Ifosfamide in treatment of refractory breast cancer. Methods 98 cases of breast cancer in the Second Hospital of Nanjing City in Jiangsu Province from February 2014 to February 2015 were selected as the object of this study, and were divided into the control group and the observation group according to the random number table method, 49 cases in each group. The control group was treated with Gemcitabine, the observation group received Gemcitabine combined with Ifosfamide treatment. After treatment for 3 months, the clinical efficacy and adverse reactions of the two groups, and the quality of life of the patients in the two groups were compared. Results The total effective rate of the observation group was 89.8%, higher than 65.3%in the control group, with statistical difference（P〈0.05）. The observation group and the control group had different degrees of adverse reactions, with no statistical differenc（P〈0.05）. After treatment, the improvement rate of life quality of the observation group was 89.90%, significantly higher than 63.63% of the control group, with statistical difference（P〈0.05）. Conclusion Gemcitabine combined with Ifosfamide in treatment of refractory breast cancer has obvious effect,and low incidence rate of adverse reaction, can significantly improve the quality of life of patients, is conducive to the recovery of patients, for clinical refractory breast cancer drug combination scheme to provide reference.